bioMérieux S.A.

Paris Stock Exchange BIM.PA

bioMérieux S.A. Price to Earnings Ratio (P/E) on January 14, 2025: 33.13

bioMérieux S.A. Price to Earnings Ratio (P/E) is 33.13 on January 14, 2025, a 1.93% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

bioMérieux S.A. 52-week high Price to Earnings Ratio (P/E) is 36.46 on September 12, 2024, which is 10.05% above the current Price to Earnings Ratio (P/E).
bioMérieux S.A. 52-week low Price to Earnings Ratio (P/E) is 28.44 on June 21, 2024, which is -14.18% below the current Price to Earnings Ratio (P/E).
bioMérieux S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is 32.40.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Paris Stock Exchange: BIM.PA

bioMérieux S.A.

CEO	Mr. Pierre Boulud
IPO Date	July 7, 2004
Location	France
Headquarters	376 Chemin De l'Orme
Employees	13,409
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Key trends

Past 5 years